Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Comparative Characteristics of the Effectiveness of Tyrosine Kinase Inhibitors Vs Allogeneic Hematopoietic Stem Cell Transplantation in the Chronic Phase of Chronic Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 12192–12193.

https://doi.org/10.1182/blood-2022-163506

Published: 2022

Journal Articles

Next-Generation Sequencing in Non- BCR-ABL Mechanisms Resistance in Patients with Chronic Myeloid Leukemia: Results of a Pilot Study

Ilya Buldakov, Sergey Voloshin, MD PhD, Mikhail Fominykh, MD, Vasily Shuvaev, MD, Sergey Petrov, Alexander Chechetkin, MD PhD, Irina Martynkevich, MD PhD

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-142391

Published: 2020

Journal Articles

Next-Generation Sequencing Targeted Chronic Lymphocytic Leukemia Panel: A Pilot Study

Mariia Mikhaleva, MD, Irina Martynkevich, MD PhD, Sergey Petrov, Ilya Buldakov, Alexey Kuvshinov, MD, Vasily Shuvaev, MD, Alexander Chechetkin, MD PhD, Sergey Voloshin, MD PhD

Blood (2020) 136 (Supplement 1): 19.

https://doi.org/10.1182/blood-2020-139418

Published: 2020

Journal Articles

The Prognostic Significance of Minimal Residual Disease in Multiple Myeloma in the Molecular Genetic Groups Msmart 3.0

Andrey Garifullin, MD, Sergei Voloshin, MD PhD, Sergey Linnikov, Irina Martynkevich, MD PhD, Alexey Kuvshinov, MD, Anastasiya Kuzyaeva, Zhanna Chubukina, Vasily Shuvaev, MD, Elizaveta Kleina, Marina Bakai, Alexander Sсhmidt

Blood (2020) 136 (Supplement 1): 42.

https://doi.org/10.1182/blood-2020-139239

Published: 2020

Journal Articles

Significance of Modified Risk Stratification Msmart 3.0 and Autologous Stem Cell Transplantation for Patients with Newly Diagnosed Multiple Myeloma

Andrey Garifullin, MD, Sergei Voloshin, MD PhD, Vasily Shuvaev, MD, Irina Martynkevich, MD PhD, Elizaveta Kleina, Alexander Chechetkin, Stanislav Bessmeltcev, Anastasiya Kuzyaeva, Alexander Sсhmidt, Alexey Kuvshinov, MD, Irina Pavlova

Blood (2019) 134 (Supplement_1): 5593.

https://doi.org/10.1182/blood-2019-130092

Published: 2019

Journal Articles

Maintenance Therapy in Patients with Chronic Lymphocytic Leukemia Who Achieved MRD-Positive Remissions after Induction Therapy

Alexey Kuvshinov, MD, Sergei Voloshin, MD PhD, Vasily Shuvaev, MD, Elena Belyakova, MD, Mariia Mikhaleva, MD, Andrey Garifullin, MD, Georgiy Rysev, MD, Alexander Bogdanov, MD PhD, Irina Martynkevich, MD PhD, Elizaveta Kleina, Alena Samorodova, MD, Iuliia Ruzhenkova, Iuliia Vokueva, Alexander Chechetkin

Blood (2019) 134 (Supplement_1): 5475.

https://doi.org/10.1182/blood-2019-129995

Published: 2019

Journal Articles

Influence of Minimal Residual Disease on Survival of Patients with Mantle Cell Lymphoma

Mariia Mikhaleva, MD, Alexey Kuvshinov, MD PhD, Alexander Schmidt, Vasily Shuvaev, MD, Karina Krutikova, MD, Elena Belyakova, Irina Martynkevich, MD PhD, Alexander Chechetkin, Sergei Voloshin, MD PhD

Blood (2018) 132 (Supplement 1): 1611.

https://doi.org/10.1182/blood-2018-99-119761

Published: 2018

Journal Articles

Russian Experience of Bosutinib Use in Chronic Myeloid Leukemia Patients in Routine Clinical Practice

Vasily Shuvaev, MD, Olga Vinogradova, MD PhD, Irina Martynkevich, MD PhD, Novitskaya Natalya, MD, Mikhail Fominykh, MD, Svetlana Tsareva, Dzhariyat Shikhbabaeva, Maria Pankrashkina, Mikhail Chernikov, Nikolay Sharkunov, MD PhD, Irina Zotova, MD, Vera Udaleva, MD PhD, Ekaterina Motyko, MD, Sergei Voloshin, MD PhD

Blood (2018) 132 (Supplement 1): 5446.

https://doi.org/10.1182/blood-2018-99-114164

Published: 2018

Journal Articles

Role of Molecular Drivers in Coagulation By Integral Assessment in Primary Myelofibrosis Patients

Elizaveta Efremova, MD, Olesya Matvienko, MD, Natalya Korsakova, Mikhail Fominykh, MD, Natalya Silina, Ludmila Papayan, Lyubov Polushkina, MD, Ekaterina Motyko, MD, Irina Martynkevich, MD PhD, Vasily Shuvaev, MD, Sergei Voloshin, MD PhD

Blood (2018) 132 (Supplement 1): 5473.

https://doi.org/10.1182/blood-2018-99-118801

Published: 2018

Journal Articles

Atypical Chronic Myeloid Leukemia Challenge in Russian Hematology Practice

Vasily Shuvaev, MD, Karina Krutikova, MD, Svetlana Menshakova, MD, Natalya Kalinova, MD, Irina Martynkevich, MD PhD, Lyubov Polushkina, MD, Elena Belyakova, MD, Yury Krivolapov, MD PhD, Sergei Voloshin, MD PhD

Blood (2018) 132 (Supplement 1): 5483.

https://doi.org/10.1182/blood-2018-99-114885

Published: 2018

Journal Articles

Baseline Cytogenetic Response Is a Predictor of Outcome of Third Line 2 nd Generation TKI Treatment in Chronic Phase Chronic Myeloid Leukemia Patients

Natalia Lazorko, MD, Elza Lomaia, MD, Vasily Shuvaev, MD PhD, Irina Martynkevich, Mikhail Fominykh, MD, Anna Silyutina, MD, Katerina Ovsiannikova, Nadia Siordia, MD, Andrey Zaritskey, Elena Machulaytene, MD

Blood (2017) 130 (Supplement 1): 5255.

https://doi.org/10.1182/blood.V130.Suppl_1.5255.5255

Published: 2017

Journal Articles

Prognostic Impact of Distinct Combinations of Molecular Mutations in AML Patients. Results of Two-Center International Cooperation Study

Olga Blau, MD PhD, Irina Martynkevich, MD PhD, Franziska Behrenbeck, Claudia D. Baldus, MD, Ekaterina Motiko, Sergei Voloshin, MD PhD, Antonio Pezzutto, MD PhD, Bernd Dorken, MD PhD, Igor Wolfgang Blau, MD PhD

Blood (2017) 130 (Supplement 1): 5111.

https://doi.org/10.1182/blood.V130.Suppl_1.5111.5111

Published: 2017

Journal Articles

Minimal Residual Disease in Multiple Myeloma Patients: Influence on Indicators of Progression Free Survival

Andrei Garifullin, Sergei Voloshin, Irina Martynkevich, DSc, Alexey Kuvshinov, Elizaveta Kleina, Vasily Shuvaev, MD, Kudrat Abdulkadyrov, Prof., MD PhD

Blood (2016) 128 (22): 5705.

https://doi.org/10.1182/blood.V128.22.5705.5705

Published: 2016

Journal Articles

Influence of JAK2V617F Allele Burden on Hematological Response in the Treatment of Polycythemia Vera

Dzhariyat Shikhbabaeva, MD, Vasily Shuvaev, MD, Regina Golovchenko, MD PhD, Vera Udaleva, MD, Mikhail Fominykh, MD, Irina I Zotova, MD, Lyubov Polushkina, MD, Irina Martynkevich, DSc, Kudrat Abdulkadyrov, MD PhD

Blood (2016) 128 (22): 5475.

https://doi.org/10.1182/blood.V128.22.5475.5475

Published: 2016

Journal Articles

Ibrutinib-Based Therapy in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia

Alexey Kuvshinov, Sergei Voloshin, Irina Martynkevich, DSc, Ludmila Martynenko, Andrei Garifullin, Elizaveta Kleina, Vasily Shuvaev, MD

Blood (2016) 128 (22): 5599.

https://doi.org/10.1182/blood.V128.22.5599.5599

Published: 2016

Journal Articles

Impact of Simultaneous Presence of Additional Chromosome Aberrations and BCR-ABL1 Kinase Domain Mutations on Survival in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Mikhail Fominykh, MD, Vasily Shuvaev, MD, Irina Martynkevich, DSc, Oleg Shukhov, MD, Ekaterina Chelysheva, MD, Anna G Turkina, Prof., MD, Kudrat Abdulkadyrov, Prof., MD PhD

Blood (2016) 128 (22): 5437.

https://doi.org/10.1182/blood.V128.22.5437.5437

Published: 2016

Journal Articles

Prognosis in Primary Myelofibrosis Patients According to Cytogenetic and Molecular Testing Results

Liubov Polushkina, Irina Martynkevich, DSc, Vasily Shuvaev, MD, Mikhail Fominykh, MD, Dzhariyat Shikhbabaeva, MD, Ekaterina Motyko, PhD, Lyudmila Martynenko, Natalya Cybakova, PhD, Marina Ivanova, MD PhD, Elena Shabanova, Anastasya Zhernyakova, Alsu Savrilova, Kudrat Abdulkadyrov, Prof., MD PhD

Blood (2016) 128 (22): 5467.

https://doi.org/10.1182/blood.V128.22.5467.5467

Published: 2016

Journal Articles

The Devil Is Not As Black As He Is Painted - 3-Year Experience of Treating Newly Diagnosed CML Patients with Imatinib Generics

Vasily Shuvaev, MD, Mikhail Fominykh, MD, Vera Udaleva, MD, Irina I Zotova, MD, Regina Golovchenko, MD PhD, Dzhariyat Shikhbabaeva, MD, Irina Martynkevich, DSc, Lyudmila Martynenko, Marina Ivanova, MD PhD, Natalya Tsybakova, PhD, Ekaterina Motyko, PhD, Lyubov Polushkina, MD, Nadezhda Potikhonova, MD PhD, Sophya Tyranova, MD PhD, Marina Zenina, MD PhD, Kudrat Abdulkadyrov, MD PhD

Blood (2016) 128 (22): 5441.

https://doi.org/10.1182/blood.V128.22.5441.5441

Published: 2016

Journal Articles

It Is Safe to Change Horses in the Midstream - 3-Year Experience of Treating CML Patients with Imatinib Generics

Blood (2016) 128 (22): 5442.

https://doi.org/10.1182/blood.V128.22.5442.5442

Published: 2016

Journal Articles

The Rate of Individual BCR-ABL Decline As an Optimized Predictor of Tyrosine Kinase Inhibitors Treatment Outcome in Chronic Phase CML Patients, Comparison with CML Prognostic Scores and Early Molecular Response Achievement

Blood (2015) 126 (23): 5150.

https://doi.org/10.1182/blood.V126.23.5150.5150

Published: 2015

NARROW

Comparative Characteristics of the Effectiveness of Tyrosine Kinase Inhibitors Vs Allogeneic Hematopoietic Stem Cell Transplantation in the Chronic Phase of Chronic Myeloid Leukemia

Next-Generation Sequencing in Non- BCR-ABL Mechanisms Resistance in Patients with Chronic Myeloid Leukemia: Results of a Pilot Study

Next-Generation Sequencing Targeted Chronic Lymphocytic Leukemia Panel: A Pilot Study

The Prognostic Significance of Minimal Residual Disease in Multiple Myeloma in the Molecular Genetic Groups Msmart 3.0

Significance of Modified Risk Stratification Msmart 3.0 and Autologous Stem Cell Transplantation for Patients with Newly Diagnosed Multiple Myeloma

Maintenance Therapy in Patients with Chronic Lymphocytic Leukemia Who Achieved MRD-Positive Remissions after Induction Therapy

Influence of Minimal Residual Disease on Survival of Patients with Mantle Cell Lymphoma

Russian Experience of Bosutinib Use in Chronic Myeloid Leukemia Patients in Routine Clinical Practice

Role of Molecular Drivers in Coagulation By Integral Assessment in Primary Myelofibrosis Patients

Atypical Chronic Myeloid Leukemia Challenge in Russian Hematology Practice

Baseline Cytogenetic Response Is a Predictor of Outcome of Third Line 2 nd Generation TKI Treatment in Chronic Phase Chronic Myeloid Leukemia Patients

Prognostic Impact of Distinct Combinations of Molecular Mutations in AML Patients. Results of Two-Center International Cooperation Study

Minimal Residual Disease in Multiple Myeloma Patients: Influence on Indicators of Progression Free Survival

Influence of JAK2V617F Allele Burden on Hematological Response in the Treatment of Polycythemia Vera

Ibrutinib-Based Therapy in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia

Impact of Simultaneous Presence of Additional Chromosome Aberrations and BCR-ABL1 Kinase Domain Mutations on Survival in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Prognosis in Primary Myelofibrosis Patients According to Cytogenetic and Molecular Testing Results

The Devil Is Not As Black As He Is Painted - 3-Year Experience of Treating Newly Diagnosed CML Patients with Imatinib Generics

It Is Safe to Change Horses in the Midstream - 3-Year Experience of Treating CML Patients with Imatinib Generics

The Rate of Individual BCR-ABL Decline As an Optimized Predictor of Tyrosine Kinase Inhibitors Treatment Outcome in Chronic Phase CML Patients, Comparison with CML Prognostic Scores and Early Molecular Response Achievement

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only